Medicenna Therapeutics is an immunotherapy company developing interleukin-2, interleukin-4 and interleukin-13 tunable cytokines, called Superkines. These Superkines can be developed either on their own as short or long-acting therapeutics or fused with cell killing proteins in order to generate Empowered Superkines that deliver potent toxins to cancer cells. Superkines can also be fused with proteins, antibodies and other Superkines in order to incorporate two synergistic therapeutic activities into one molecule, creating Bi-Functional SuperKine ImmunoTherapies referred by Medicenna as BiSKITs. Co.'s Product Candidate, MDNA55, is used for the treatment of tumors of the brain in adults. The MDNA stock yearly return is shown above.
The yearly return on the MDNA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MDNA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|